Cargando…

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells

Pancreatic ductal adenocarcinoma (PDAC) is the 4(th) leading cause of cancer-related death in Western countries with a 5-year survival rate below 5%. One of the hallmarks of this cancer is the strong desmoplastic reaction within the tumor microenvironment (TME), orchestrated by activated pancreatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Audenaerde, Jonas R.M., De Waele, Jorrit, Marcq, Elly, Van Loenhout, Jinthe, Lion, Eva, Van den Bergh, Johan M.J., Jesenofsky, Ralf, Masamune, Atsushi, Roeyen, Geert, Pauwels, Patrick, Lardon, Filip, Peeters, Marc, Smits, Evelien L.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593617/ https://www.ncbi.nlm.nih.gov/pubmed/28915646 http://dx.doi.org/10.18632/oncotarget.18185

Ejemplares similares

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells
por: Van Loenhout, Jinthe, et al.
Publicado: (2019)

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment
por: Van Audenaerde, Jonas RM, et al.
Publicado: (2020)

Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer
por: Flieswasser, Tal, et al.
Publicado: (2020)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

The CD70-CD27 axis in oncology: the new kids on the block
por: Flieswasser, Tal, et al.
Publicado: (2022)

Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma
por: Van Loenhout, Jinthe, et al.
Publicado: (2021)

Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects
por: Van Loenhout, Jinthe, et al.
Publicado: (2020)

Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers
por: Freire Boullosa, Laurie, et al.
Publicado: (2023)

Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model
por: Freire Boullosa, Laurie, et al.
Publicado: (2022)

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
por: Zaryouh, Hannah, et al.
Publicado: (2022)

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer
por: Freire Boullosa, Laurie, et al.
Publicado: (2021)

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
por: Deben, Christophe, et al.
Publicado: (2018)

Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer
por: Domen, Andreas, et al.
Publicado: (2021)

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
por: Verhoeven, Yannick, et al.
Publicado: (2021)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy
por: De Waele, Jorrit, et al.
Publicado: (2021)

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?
por: Siozopoulou, Vasiliki, et al.
Publicado: (2021)

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
por: Versteven, Maarten, et al.
Publicado: (2018)

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
por: Rovers, Sophie, et al.
Publicado: (2022)

The effect of local non‐thermal plasma therapy on the cancer‐immunity cycle in a melanoma mouse model
por: Lin, Abraham, et al.
Publicado: (2022)

The Influence of Cell Type and Culture Medium on Determining Cancer Selectivity of Cold Atmospheric Plasma Treatment
por: Biscop, Eline, et al.
Publicado: (2019)

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer
por: Flieswasser, Tal, et al.
Publicado: (2023)

Non‐Thermal Plasma as a Unique Delivery System of Short‐Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells
por: Lin, Abraham, et al.
Publicado: (2019)

The prognostic impact of the immune signature in head and neck squamous cell carcinoma
por: Baysal, Hasan, et al.
Publicado: (2022)

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
por: Jacobs, Julie, et al.
Publicado: (2015)

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects
por: Siozopoulou, Vasiliki, et al.
Publicado: (2022)

1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022)

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies
por: Baysal, Hasan, et al.
Publicado: (2021)

Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol
por: Sorber, Laure, et al.
Publicado: (2019)

Cold Atmospheric Plasma Treatment for Pancreatic Cancer–The Importance of Pancreatic Stellate Cells
por: Verloy, Ruben, et al.
Publicado: (2020)

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
por: Jacobs, Julie, et al.
Publicado: (2015)

Pancreatic Stellate Cells and Metabolic Alteration: Physiology and Pathophysiology
por: Hamada, Shin, et al.
Publicado: (2022)

Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
por: Baay, Marc, et al.
Publicado: (2011)

Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy
por: Deben, Christophe, et al.
Publicado: (2022)

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells
por: Willemen, Yannick, et al.
Publicado: (2016)

Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity
por: Van den Bergh, Johan, et al.
Publicado: (2015)

Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
por: Van Acker, Heleen H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g7sa3fpse76fd52a3om46sg0dq